Bermekimab Goes to Janssen for up to $1.35b in Deal that Could Shake up Future Hidradenitis Suppurativa & Atopic Dermatitis Market

XBiotech’s Bermekimab, a promising experimental drug generating significant interest with Hidradenitis Suppurativa patients in the TrialSite News network, has been sold to Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. Bermekimab is...

Pin It on Pinterest